Lotte R, Lotte L, Ruimy R
Department of Bacteriology at Nice Academic Hospital, Nice, France; Nice Medical University, Nice-Sophia Antipolis University, Nice, France; INSERM U1065 (C3M), Bacterial Toxins in Host Pathogen Interactions, C3M, Bâtiment Universitaire Archimed, Nice, France.
Department of Bacteriology at Nice Academic Hospital, Nice, France; Nice Medical University, Nice-Sophia Antipolis University, Nice, France.
Clin Microbiol Infect. 2016 Jan;22(1):28-36. doi: 10.1016/j.cmi.2015.10.038. Epub 2015 Nov 11.
The genus Actinotignum contains three species, Actinotignum schaalii (formerly Actinobaculum schaalii), Actinotignum urinale and Actinotignum sanguinis. A. schaalii is the species most frequently involved in human infections, with 172 cases, mostly urinary tract infections (UTIs), reported so far. Invasive infections have also been described. This facultative anaerobic Gram-positive rod is part of the urinary microbiota of healthy patients. It is responsible for UTIs, particularly in elderly men and young children. A. schaalii is an underestimated cause of UTIs because of its fastidious growth on usual media and difficulties associated with its identification using phenotypic methods. Indeed, this slow-growth bacterium requires blood-enriched media and an incubation time of 48 hours under anaerobic or 5% CO2 atmosphere. Furthermore, only matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) or molecular-based methods allow the accurate identification of this bacteria. MALDI-TOF using Microflex LT with the Biotyper database (Bruker Daltonics, Bremen, Germany) is the most reliable technology for the routine identification of A. schaalii. The identification of this uropathogen is all the more important because it is resistant to trimethoprim/sulfamethoxazole and second-generation quinolones that are widely used in the treatment of UTIs. Antimicrobial therapy using β-lactams prolonged for up to 2 weeks is the most efficient treatment and should be recommended. Microbiologists should assess the presence of A. schaalii in urine using appropriate culture and identification methods in the case of a direct examination that is positive for small coccoid rods, a negative nitrite urinary stick associated with leukocyturia, treatment failure with trimethoprim/sulfamethoxazole or fluoroquinolones, or undocumented, repeated UTIs.
放线杆菌属包含三个菌种,即沙氏放线杆菌(以前称为 Schaali 放线杆菌)、尿道放线杆菌和血放线杆菌。沙氏放线杆菌是最常引起人类感染的菌种,迄今为止已报告 172 例病例,主要为尿路感染(UTI)。也有侵袭性感染的报道。这种兼性厌氧革兰氏阳性杆菌是健康患者泌尿微生物群的一部分。它是尿路感染的病因,尤其在老年男性和幼儿中。由于沙氏放线杆菌在常规培养基上生长挑剔,且使用表型方法进行鉴定存在困难,因此它是一种被低估的尿路感染病因。实际上,这种生长缓慢的细菌需要富含血液的培养基,并在厌氧或 5%二氧化碳气氛下孵育 48 小时。此外,只有基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF)或基于分子的方法才能准确鉴定这种细菌。使用配备 Biotyper 数据库(德国不来梅的布鲁克道尔顿公司)的 Microflex LT 的 MALDI-TOF 是常规鉴定沙氏放线杆菌最可靠的技术。这种尿路病原体的鉴定尤为重要,因为它对广泛用于治疗尿路感染的甲氧苄啶/磺胺甲恶唑和第二代喹诺酮类药物耐药。使用β-内酰胺类药物延长治疗长达 2 周是最有效的治疗方法,应予以推荐。在直接检查发现小的球杆状菌呈阳性、尿亚硝酸盐试纸阴性且伴有白细胞尿、甲氧苄啶/磺胺甲恶唑或氟喹诺酮类药物治疗失败,或未记录的反复尿路感染的情况下,微生物学家应使用适当的培养和鉴定方法评估尿液中沙氏放线杆菌的存在。